229. 肺胞蛋白症（自己免疫性又は先天性） Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details

臨床試験数 : 44 / 薬物数 : 22 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01511068 (ClinicalTrials.gov)	August 2012	12/12/2011	Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)	Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)	Hereditary Pulmonary Alveolar Proteinosis	Drug: Leukine	Children's Hospital Medical Center, Cincinnati	Virginia Commonwealth University;Genzyme, a Sanofi Company	Completed	8 Years	N/A	All	2	Phase 2	United States
2	EUCTR2008-007086-23-IT (EUCTR)	12/12/2008	27/01/2009	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP	Autoimmune PAP MedDRA version: 9.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis	Trade Name: Leukine INN or Proposed INN: Sargramostim	OSPEDALE POLICLINICO S. MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy